COVID-19 Vaccines - Switzerland

Switzerland

Highlights

In Switzerland, the revenue in the COVID-19 Vaccines market is estimated to reach US$71.33m in 2024.
It is projected that the revenue will experience a steady annual growth rate (CAGR 2024-2029) of -17.88%.
This growth will lead to a market volume of US$26.63m by 2029.
When compared to other countries, United States is expected to generate the highest revenue of US$4.39bn in 2024.
Switzerland's efficient healthcare system and high vaccine uptake rate contribute to the successful distribution and administration of COVID-19 vaccines in the country.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

Switzerland, a country known for its chocolates, watches, and banking system, has been making strides in its COVID-19 vaccination efforts.

Customer preferences: Switzerland has a population of approximately 8.5 million people, and as of August 2021, over 52% of the population has been fully vaccinated against COVID-19. The Swiss government has been actively promoting vaccination and has made it easily accessible to the public. The country has also been administering vaccines to refugees and asylum seekers, ensuring that everyone has access to the vaccine regardless of their legal status.

Trends in the market: The COVID-19 vaccine market in Switzerland has been dominated by Pfizer-BioNTech and Moderna vaccines. These two vaccines have been the most widely used in the country due to their high efficacy rates and safety profiles. Recently, Switzerland has also approved the use of the Johnson & Johnson vaccine, adding to the available options for the public.

Local special circumstances: Switzerland has a highly developed healthcare system, which has allowed for efficient vaccine distribution and administration. The country has also been proactive in securing vaccine doses, ensuring that there is a sufficient supply for the population. Additionally, Switzerland has experienced a relatively low incidence rate of COVID-19 compared to other countries, which has allowed for a more targeted vaccination approach.

Underlying macroeconomic factors: Switzerland has a strong economy and has been able to invest in its healthcare system, which has contributed to the success of its vaccination efforts. The country has also been able to secure a steady supply of vaccines due to its high purchasing power. Furthermore, Switzerland has a highly educated population, which has led to a high level of vaccine acceptance and compliance.In conclusion, Switzerland has been successful in its COVID-19 vaccination efforts due to its advanced healthcare system, proactive government measures, and high level of vaccine acceptance among the population. The country's success in vaccine distribution and administration can serve as an example for other countries looking to improve their vaccination rates and control the spread of COVID-19.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.